Samuel J. Klempner, MD

A recent trial reveals that durvalumab enhances event-free survival in patients with resectable gastric and gastroesophageal junction adenocarcinoma.

Samuel Klempner, MD, explains the rationale for the phase 3 SPOTLIGHT study.

Samuel Klempner, MD, discusses zolbetuximab for patients with claudin 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction cancer.

Samuel J. Klempner, MD, discusses the preliminary results of a study of the investigational agent DKN-01 for patients with gastroesophageal adenocarcinoma.

Samuel J. Klempner, MD, discusses the mechanism of action of the investigational agent DKN-01 in patients with gastroesophageal adenocarcinoma.

Samuel J. Klempner, MD, discusses unmet needs in patients with gastroesophageal adenocarcinoma when it comes to biomarker-targeted agents.